[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340685-105":59,"doc-detail-340685-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cubosomes-as-delivery-system-to-repositioning-nitrofurantoin-in-breast-cancer-management","Cubosomes as Delivery System to Repositioning Nitrofurantoin in Breast Cancer Management","","Purpose focuses on leveraging nitrofurantoin’s nitro-reductase activation to repurpose the drug for breast cancer, a disease expressing a nitro reductase gene. Methods develop NITRO cubosomes via hot homogenization using a 2 3-full factorial design, evaluating 8 formulations by particle size, zeta potential, polydispersity index, and entrapment efficiency. Results identify S6 as optimal, showing 45.5 ± 1.1 nm and 98.6 ± 1.8% entrapment, with TEM-confirmed morphology and MTT-driven intracellular efficacy against MCF-7 cells. Conclusion supports further stability and in vivo studies for repositioning.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cubosomes-as-delivery-system-to-repositioning-nitrofurantoin-in-breast-cancer-management/340685/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cubosomes-as-delivery-system-to-repositioning-nitrofurantoin-in-breast-cancer-management/340685.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main purpose?","Question",{"text":112,"@type":113},"The study aims to reposition nitrofurantoin for breast cancer by using cubosomes, leveraging nitrofurantoin activation through nitro reductase enzymes expressed in the disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were NITRO cubosomes formulated and evaluated?",{"text":117,"@type":113},"NITRO cubosomes were prepared by hot homogenization using a 2-3 full factorial design, varying drug-to-oily phase, oily-to-aqueous phase, and GMO-to-PX407 ratios. Eight systems were evaluated using particle size, zeta potential, polydispersity index, and entrapment efficiency.",{"name":119,"@type":110,"acceptedAnswer":120},"Which formulation showed the best performance, and what evidence supported it?",{"text":121,"@type":113},"Formulation S6 showed the highest desirability with 45.5 ± 1.1 nm particle size and 98.6 ± 1.8% entrapment efficiency. TEM assessed morphology, and an MTT assay on MCF-7 cells indicated the lowest IC50 compared with free nitrofurantoin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340685,1790420545,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Drug Design, Development and Therapy Dovepress  \n Open Access Full Text Article ORIGINAL RESEARCH  \nCubosomes as Delivery System to Repositioning Nitrofurantoin in Breast Cancer Management  \nDina Louis 1 , 2 , *, Christianne Mounir Zaki Rizkalla 1 , Amira Rashad 3 , *  \n1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt; 2Department of Pharmaceutics, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Cairo, Egypt; 3Department of Pharmaceutical Technology, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt  \n*These authors contributed equally to this work  \nCorrespondence: Dina Louis, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr Eleini Street, Cairo, 11562, Egypt, Tel +202 01228866769, Email [dina.nassif@pharma.cu.edu.eg](dina.nassif@pharma.cu.edu.eg)  \n\n| Purpose: Nitrofurantoin (NITRO), a long-standing antibiotic to treat urinary tract infections, is activated by Nitro reductases. This activation mechanism has led to its exploration for repositioning applications in controlling and treating breast cancer, which express a Nitro reductase gene.\u003Cbr>Methods: NITRO Cubosomes were developed using hot homogenization according to 23-full factorial design. The factors studied included the ratio of drug to oily phase (1:10 and 2:10), the ratio of oily to aqueous phase (1:10 and 1:5), and the ratio of Glyceryl mono-oleate (GMO) to Poloxamer 407 (PX407) (0.25:1 and 0.5:1) . A total of 8 systems were proposed and evaluated by measuring particle size, zeta potential, polydispersity index, and percentage of entrapment efficiency.\u003Cbr>Results: S6 (1:10 drug: oily phase, 1:5 oily: aqueous phase and 0.5:1 GMO: PX407) with particle size 45.5 ±c1.1 nm and an entrapment efficiency of 98.6 ± 1.8% exhibited highest desirability and was selected for further analysis. The morphology of S6 was examined using TEM microscopy. The activation of NITRO from S6 reflected on intracellular viability of MCF-7 breast cancer cell line was investigated by an MTT assay. The findings indicated that S6 had the lowest IC50 value (83.99 ± 0.15 μg g/mL) compared to Free NITRO (174.54 ± 1.36 μg g/mL), suggesting enhanced efficacy compared to free NITRO.\u003Cbr>Conclusion: Nitrofurantoin cubosomes can be candidates for repositioning in breast cancer management after encouraging further stability and in-vivo studies.\u003Cbr>Keywords: nitro reductase, glyceryl monooleate, Poloxamer 407, MTT assay, factorial design |\n| --- |\n| Introduction\u003Cbr>Cancer, a complex and multifactorial disease, includes the abnormal, uncontrollable cell growth and a continuous change in cell genome, resulting in the appearance of cancerous features within normal cells.1,2 The main approach of any cancer therapy is to limit tumour growth, metastases, and prevent retrogression after elimination, resulting in prolongation of the life of the patient.3 There are problems associated with common methods used in cancer therapy such as surgery, chemotherapy, and radiation. These problems include resistance to treatment, major side effects and absence of specific site delivery.4 Hence, these methods are usually insufficient to produce results satisfactory to the patients. That necessitated the conduction of new studies to discover novel treatments.5\u003Cbr>It was reported by the World Health Organization that about 2.3 million women suffered from breast cancer in 2020 and 0.5 million deaths annually.6,7 A widely used treatment is radiotherapy,8 in addition to several conventional chemotherapies.9 The use of nano-carriers has been introduced in cancer therapy.10 These involved the application of liposomes, polymeric nanoparticles, polymeric micelles, dendrimers, 11 magnetic nanoparticles, 12 and pH-sensitive nanovehicles.13 Photodynamic therapy has also been introduced as an effective treatment for cancer.14 It involves the use of laser light, which is a specific and readily acceptable treat","cbCaib2Rwf2paAsO","https://ap.wps.com/l/cbCaib2Rwf2paAsO","pdf",6308909,12,"English","# Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Drug repositioning concept\n## Nitrofurantoin mechanism","[{\"question\":\"What is the study’s main purpose?\",\"answer\":\"The study aims to reposition nitrofurantoin for breast cancer by using cubosomes, leveraging nitrofurantoin activation through nitro reductase enzymes expressed in the disease.\"},{\"question\":\"How were NITRO cubosomes formulated and evaluated?\",\"answer\":\"NITRO cubosomes were prepared by hot homogenization using a 2-3 full factorial design, varying drug-to-oily phase, oily-to-aqueous phase, and GMO-to-PX407 ratios. Eight systems were evaluated using particle size, zeta potential, polydispersity index, and entrapment efficiency.\"},{\"question\":\"Which formulation showed the best performance, and what evidence supported it?\",\"answer\":\"Formulation S6 showed the highest desirability with 45.5 ± 1.1 nm particle size and 98.6 ± 1.8% entrapment efficiency. TEM assessed morphology, and an MTT assay on MCF-7 cells indicated the lowest IC50 compared with free nitrofurantoin.\"}]","Cubosomes as Delivery System to Repositioning Nitrofurantoin in Breast Cancer Management | PDF",1790038204,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33b242f1eaf0f15de3e66917038c98e4.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f70af41f7aa27c56c575dc164f70134b.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cba2b05569f2ef2321b9c54c5a61c4a8.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ab321edec9febf48b6fa31814a27d6c.webp",980,1268]